

2019 HEDIS® MEASURE: ANNUAL MONITORING FOR PATIENTS ON PERSISTENT MEDICATIONS (MPM)

Gold Coast Health Plan's goal is to help its providers gain compliance with their annual Healthcare Effectiveness Data and Information Set (HEDIS®) scores. This tip sheet will provide the key components to the HEDIS® measure, "Annual Monitoring for Patients on Persistent Medications (MPM)."

Measure Description: Measures the percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year.

- ▶ Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB)
- ▶ Annual monitoring for members on diuretics

Annual monitoring

Ambulatory therapeutic agent (medication)	Therapeutic monitoring event
ACE inhibitors or ARBs	At least one serum potassium and a serum creatinine therapeutic monitoring test. Any of the following will meet compliance: <ul style="list-style-type: none"> • A lab panel test • A serum potassium test and a serum creatinine test <i>The tests do not need to occur on the same service date, only within the measurement year.</i>
Diuretic	At least one serum potassium and a serum creatinine therapeutic monitoring test. Any of the following will meet compliance: <ul style="list-style-type: none"> • A lab panel test • A serum potassium test and a serum creatinine test <i>The tests do not need to occur on the same service date, only within the measurement year.</i>

Codes used to identify therapeutic monitoring events

Description	CPT	LOINC
Lab Panel	80047, 80048, 80050, 80053, 80069	
Serum Potassium	80051, 84132	12812-4, 12813-2, 2823-3, 2824-1, 29349-8, 32713-0, 39789-3, 39790-1, 41656-0, 51618-7, 6298-4, 75940-7, 82722-0
Serum Creatinine	82565, 82575	11041-1, 11042-9, 12195-4, 13441-1, 13442-9, 13443-7, 13446-0, 13447-8, 13449-4, 13450-2, 14682-9, 16188-5, 16189-3, 21232-4, 2160-0, 2163-4, 2164-2, 26752-6, 31045-8, 33558-8, 35203-9, 35591-7, 35592-5, 35593-3, 35594-1, 38483-4, 39955-0, 39956-8, 39957-6, 39958-4, 39959-2, 39960-0, 39961-8, 39962-6, 39963-4, 39964-2, 39965-9, 39966-7, 39967-5, 39968-3, 39969-1, 39970-9, 39971-7, 39972-5, 39973-3, 39974-1, 39975-8, 39976-6, 40112-5, 40113-3, 40114-1, 40115-8, 40116-6, 40117-4, 40118-2, 40119-0, 40120-8, 40121-6, 40122-4, 40123-2, 40124-0, 40125-7, 40126-5, 40127-3, 40128-1, 40248-7, 40249-5, 40250-3, 40251-1, 40252-9, 40253-7, 40254-5, 40255-2, 40256-0, 40257-8, 40258-6, 40264-4, 40265-1, 40266-9, 40267-7, 40268-5, 40269-3, 40270-1, 40271-9, 40272-7, 40273-5, 44784-7, 50380-5, 50381-3, 51619-5, 51620-3, 59826-8, 59834-2, 62425-4



Important HEDIS® Specifications:

- ▶ Remember that the tests do not have to occur on the same service date; just make sure they are completed within the measurement year.
- ▶ Be mindful that patients can switch medications during the measurement year and have the days' supply for those medications count toward the total 180 treatment days (e.g., a member who received 90 days of ACE inhibitors and 90 days of ARBs will meet the denominator definition).

Best Practices:

- ▶ Educate members about the importance of periodic testing.
- ▶ Review medications and assess for potential adverse drug effects (ADEs) at every visit.
- ▶ Order monitoring tests at least yearly.
- ▶ Remember: An increase in serum creatinine of >20%-30% or an abnormal serum potassium level may be indicative of decreased kidney function and warrants appropriate follow-up.
- ▶ More information is available from the [National Kidney Foundation](#).

For additional information on specific HEDIS® measures, please visit the websites for the [National Committee for Quality Assurance \(NCQA\)](#) or the [Agency for Healthcare Research and Quality \(AHRQ\)](#).

Effective January 1, 2014, NCQA replaced the coding tables with “value sets” which contain all applicable codes that can be used to identify a specific service or condition included in any measure. Detailed information on the data sets and technical specifications can be found [here](#).

GCHP does not intend this information to be medical advice, but a tool to assist in compliance with the HEDIS® measures.